Issues
-
Cover Image
Cover Image
Anti-VEGF therapy appears to benefit patients with glioblastoma in part via its anti-edema mechanisms. The extent to which such edema reduction may benefit patients is not clear, either in terms of survival or neurological function. In a study of 30 patients treated with cediranib, imaging changes after one day of treatment correlated with progression-free and overall survival, and a “vascular normalization index” that combines imaging and blood biomarkers was highly correlated with these long-term outcomes. Imaging can assess a variety of mechanisms of anti-VEGF therapies, and one such imaging method is diffusion tensor imaging, a method particularly suited for visualizing white matter tracts and the edema which may surround and possibly impair them. The cover image shows diffusion tractography before (top) and four months after treatment with cediranib (bottom), with re-emergence of the white matter tracts clearly evident. The reduction in edema allows markedly improved visualization of frontal lobe white matter tracts; the direct functional significance of these changes remains to be elucidated, but cediranib and other anti-VEGF therapies have been reported to show increased overall survival in single-arm studies. Further mechanistic imaging and randomized trials are underway to better understand the potential benefit of these agents, as well as validate the predictive performance of the vascular normalization index. A movie of these data is available online through a Supplementary Data link from this article (doi: 10.1158/0008-5472.CAN-09-0814). For details, see the article by Sorensen and colleagues on page 5296 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
AACR Centennial Series
Reviews
Perspectives in Cancer Research
Meeting Report
Priority Reports
A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
Functional Phosphodiesterase 11A Mutations May Modify the Risk of Familial and Bilateral Testicular Germ Cell Tumors
Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma
Cell, Tumor, and Stem Cell Biology
Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes
Smad2 and Smad3 Phosphorylated at Both Linker and COOH-Terminal Regions Transmit Malignant TGF-β Signal in Later Stages of Human Colorectal Cancer
Long-term Cultures of Bone Marrow–Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation
Nanoscale Cellular Changes in Field Carcinogenesis Detected by Partial Wave Spectroscopy
Clinical Research
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
Endocrinology
Epidemiology
Insulin-like Growth Factor-II Methylation Status in Lymphocyte DNA and Colon Cancer Risk in the Northern Sweden Health and Disease Cohort
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
Dual Activity Lysophosphatidic Acid Receptor Pan-Antagonist/Autotaxin Inhibitor Reduces Breast Cancer Cell Migration In vitro and Causes Tumor Regression In vivo
A Ruthenium-Containing Organometallic Compound Reduces Tumor Growth through Induction of the Endoplasmic Reticulum Stress Gene CHOP
Immunology
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
Molecular Biology, Pathobiology, and Genetics
ADAM23 Negatively Modulates αvβ3 Integrin Activation during Metastasis
Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression
Prevention
Tumor Microenvironment
Oncosome Formation in Prostate Cancer: Association with a Region of Frequent Chromosomal Deletion in Metastatic Disease
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.